zcl278

ZCL278 is a **selective small molecule inhibitor of the Rho family GTPase Cdc42**, specifically blocking the interaction between Cdc42 and its guanine nucleotide exchange factor intersectin (ITSN). By disrupting the Cdc42–ITSN interaction, ZCL278 inhibits Cdc42-mediated cellular processes, including actin cytoskeletal organization (such as microspike formation and Golgi structure maintenance), cellular motility, branching, and migration. It has demonstrated **anticancer properties** in prostate and lung cancer models and has also shown protective effects in a rodent model of **chronic kidney disease**, reducing inflammation and fibrosis. ZCL278 is not cytotoxic at biological concentrations and is currently used primarily as a research chemical for mechanistic studies of Cdc42 in cancer, neurological disorders, and kidney disease[1][2][3][4][5][7][10][11].

Other names

ZCL278ZCL-278ZCL 278CDC42 Inhibitor IIICDC-42 Inhibitor IIICDC 42 Inhibitor IIICDC42 GTPase Inhibitor IIICDC-42 GTPase Inhibitor IIICDC 42 GTPase Inhibitor III